Drug Trial Radar · NCT04052360
Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Aug 7, 2019
Primary completion
Oct 29, 2019
Study completion Nov 2, 2019
Sponsor
- Lead sponsor
- Viatris Innovation GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is for research purposes only and is not intended to treat any medical condition. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of cenerimod following a single dose in healthy Japanese and Caucasian participants. Pharmacokinetics is the study of the absorption and breakdown of the study drug in the body. Pharmacodynamics is the study of the effect of the study drug on the body. There will be 2 groups in the study. 10 Japanese participants in one group and 10 Caucasian participants in the other group. The duration of participation in this study is approximately 75 days from screening to the end of study visit. A screening visit is required within 21 days prior to the start of the study to determine whether the volunteer qualifies and is willing to participate in this research study. This study requires in-patient stay in the research clinic of 4 days (3 nights) followed by outpatient visits and an end of study visit 3 to 5 days after the day 49 outpatient visit.
Conditions
- Healthy Volunteers
Interventions
CenerimodDrug
A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
Matching PlaceboDrug
A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The area under the plasma concentration-time curve (AUC) for cenerimodTime frame: From Day 1 to Day 49
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.